ME01105B - Upotreba supstituisanih kinolinskih derivata za tretman bolesti uzrokovanih mikobakterijama otpornima na lekove - Google Patents

Upotreba supstituisanih kinolinskih derivata za tretman bolesti uzrokovanih mikobakterijama otpornima na lekove

Info

Publication number
ME01105B
ME01105B MEP-2008-89A MEP8908A ME01105B ME 01105 B ME01105 B ME 01105B ME P8908 A MEP8908 A ME P8908A ME 01105 B ME01105 B ME 01105B
Authority
ME
Montenegro
Prior art keywords
treatment
drug resistant
quinoline derivatives
substituted quinoline
mycobacterial diseases
Prior art date
Application number
MEP-2008-89A
Other languages
English (en)
French (fr)
Inventor
Koenraad Jozef Lodewijk Marcel Andries
Gestel Jozef Frans Elisabetha Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34929150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME01105(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ME01105B publication Critical patent/ME01105B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-2008-89A 2004-05-28 2005-05-24 Upotreba supstituisanih kinolinskih derivata za tretman bolesti uzrokovanih mikobakterijama otpornima na lekove ME01105B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04102402 2004-05-28
PCT/EP2005/052371 WO2005117875A1 (en) 2004-05-28 2005-05-24 Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
EP05743054A EP1753427B1 (en) 2004-05-28 2005-05-24 Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases

Publications (1)

Publication Number Publication Date
ME01105B true ME01105B (me) 2013-03-20

Family

ID=34929150

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2008-89A ME01105B (me) 2004-05-28 2005-05-24 Upotreba supstituisanih kinolinskih derivata za tretman bolesti uzrokovanih mikobakterijama otpornima na lekove

Country Status (35)

Country Link
US (2) US20070249667A1 (me)
EP (1) EP1753427B1 (me)
JP (2) JP5081617B2 (me)
KR (2) KR20130024969A (me)
CN (2) CN102908347A (me)
AP (1) AP2037A (me)
AR (1) AR049127A1 (me)
AT (1) ATE390925T1 (me)
AU (1) AU2005249231B2 (me)
BR (1) BRPI0510414B1 (me)
CA (1) CA2566544C (me)
CL (1) CL2009001980A1 (me)
CY (1) CY1110388T1 (me)
DE (1) DE602005005810T2 (me)
DK (1) DK1753427T3 (me)
EA (1) EA010651B1 (me)
ES (1) ES2306146T3 (me)
HK (1) HK1106136A1 (me)
HR (1) HRP20080307T3 (me)
IL (1) IL179630A (me)
JO (1) JO2524B1 (me)
ME (1) ME01105B (me)
MX (1) MXPA06013888A (me)
MY (1) MY140611A (me)
NO (1) NO338624B1 (me)
NZ (1) NZ550840A (me)
PA (1) PA8635201A1 (me)
PL (1) PL1753427T3 (me)
PT (1) PT1753427E (me)
RS (1) RS50585B (me)
SI (1) SI1753427T1 (me)
TW (1) TWI363625B (me)
UA (1) UA90267C2 (me)
WO (1) WO2005117875A1 (me)
ZA (1) ZA200609899B (me)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06013888A (es) * 2004-05-28 2007-01-26 Janssen Pharmaceutica Nv Uso de derivados de quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos.
KR101301573B1 (ko) * 2004-12-24 2013-09-04 얀센 파마슈티카 엔.브이. 잠재성 튜버큐로시스의 치료법
CA2528849C (en) 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
JP5349730B2 (ja) * 2005-06-09 2013-11-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗バクテリア剤としてのキノリン誘導体
JO2752B1 (en) 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
AP2547A (en) * 2005-06-28 2012-12-26 Janssen Pharmaceutica Nv Quinoline derivatives as antibacterial agents
JO3270B1 (ar) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
WO2007022946A1 (de) 2005-08-21 2007-03-01 Abbott Gmbh & Co. Kg Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
JO2725B1 (en) * 2006-12-06 2013-09-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2970B1 (en) * 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2684B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JO2685B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
WO2011031926A1 (en) * 2009-09-11 2011-03-17 Vertex Pharmaceuticals Incorporated Compositions of n-benzyl-3-(4-chlorophenyl)-2-[methyl-[2-oxo-2-(3,4,5-trimethoxyphenyl) acetyl]amino]-n-[3-(4-pyridyl)-1-[2-[4-pyridyl)ethyl]propanamide and uses thereof
CN102249935B (zh) * 2010-05-17 2015-05-20 中国人民解放军军事医学科学院毒物药物研究所 芳香2-丁醇类化合物及其医药用途
WO2013160431A1 (en) 2012-04-27 2013-10-31 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
DK2841425T3 (en) 2012-04-27 2016-06-27 Janssen Pharmaceutica Nv ANTIBACTERIAL QUINOLIN DERIVATIVES
BR112017000764B1 (pt) * 2014-07-14 2022-07-12 Shanghai Jia Tan Pharmatech Co. Ltd. Composto, método para preparar o composto e uso do composto
CN105330595B (zh) * 2014-07-14 2019-12-10 上海嘉坦医药科技有限公司 吡啶衍生物及其作为抗分支杆菌的应用
US20180000810A1 (en) 2015-01-27 2018-01-04 Janssen Pharmaceutica Nv Dispersible compositions
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
RU2018111482A (ru) 2015-10-20 2019-11-21 Чжэцзян Хисунь Фармасьютикал Ко., Лтд. Кристаллические формы бедаквилин фумарата и способы их получения
WO2017121323A1 (zh) * 2016-01-13 2017-07-20 辰欣药业股份有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
BR112018067922B1 (pt) * 2016-03-07 2024-02-06 The Global Alliance For Tb Drug Development, Inc Compostos antibacterianos, usos dos mesmos e composições farmacêuticas
CN107243008B (zh) * 2017-04-13 2021-03-30 中国科学院广州生物医药与健康研究院 吡唑并[1,5-a]吡啶类化合物的新应用及一种治疗脓肿分枝杆菌感染的组合物
US11407742B2 (en) * 2017-09-01 2022-08-09 The Kitasato Institute Compound having therapeutic activity against mycobacterium avium complex infection, and method for producing same
WO2020047596A1 (en) * 2018-09-04 2020-03-12 Monash University Antibacterial compounds and methods of use
KR20210113628A (ko) 2019-01-09 2021-09-16 얀센 파마슈티카 엔.브이. 비결핵성 마이코박테리아 질환의 치료에서의 조합물
WO2021107876A1 (en) * 2019-11-26 2021-06-03 Nanyang Technological University Compounds for treating tuberculosis
CN110804016B (zh) * 2019-12-05 2022-11-04 福建省微生物研究所 抗结核分枝杆菌的二芳基喹啉衍生物
KR20230107275A (ko) 2020-11-12 2023-07-14 얀센 파마슈티카 엔.브이. 비결핵성 마이코박테리아 질환의 치료에서 베다퀼린, 에탐부톨 및 마크롤라이드의 조합물
WO2023217279A1 (zh) * 2022-05-13 2023-11-16 广州嘉越医药科技有限公司 一种吡啶衍生物、中间体、制备方法和应用
CN117122595A (zh) * 2022-05-27 2023-11-28 广州嘉越医药科技有限公司 吡啶衍生物的用途
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399558A (en) * 1993-11-24 1995-03-21 Pathogenesis Corporation Isoflavonoid antibacterial compounds, compositions and use
EP0936866A4 (en) * 1996-10-28 2001-04-11 Dept Of The Army Us Government COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING ANTIBIOTIC RESIST INFECTIONS
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
SI2301544T1 (sl) * 2002-07-25 2013-01-31 Janssen Pharmaceutica, N.V. Derivati kinolina kot vmesne spojine za mikobakterijske inhibitorje
MXPA06013888A (es) * 2004-05-28 2007-01-26 Janssen Pharmaceutica Nv Uso de derivados de quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos.
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents

Also Published As

Publication number Publication date
PA8635201A1 (es) 2006-05-16
SI1753427T1 (sl) 2008-10-31
AP2037A (en) 2009-10-09
HK1106136A1 (en) 2008-03-07
TWI363625B (en) 2012-05-11
CA2566544A1 (en) 2005-12-15
JP2012229239A (ja) 2012-11-22
UA90267C2 (ru) 2010-04-26
NO20066041L (no) 2007-02-27
WO2005117875A1 (en) 2005-12-15
JO2524B1 (en) 2010-03-17
CN102908347A (zh) 2013-02-06
DE602005005810D1 (de) 2008-05-15
MXPA06013888A (es) 2007-01-26
AU2005249231A1 (en) 2005-12-15
DE602005005810T2 (de) 2009-04-09
CL2009001980A1 (es) 2010-04-16
CY1110388T1 (el) 2015-04-29
EP1753427A1 (en) 2007-02-21
PL1753427T3 (pl) 2008-09-30
AP2006003828A0 (en) 2006-12-31
TW200608974A (en) 2006-03-16
JP5675718B2 (ja) 2015-02-25
AR049127A1 (es) 2006-06-28
BRPI0510414A (pt) 2007-10-23
IL179630A (en) 2011-05-31
PT1753427E (pt) 2008-07-04
NZ550840A (en) 2010-01-29
RS50585B (sr) 2010-05-07
JP5081617B2 (ja) 2012-11-28
KR101371653B1 (ko) 2014-03-07
EP1753427B1 (en) 2008-04-02
JP2008500992A (ja) 2008-01-17
CN1976704A (zh) 2007-06-06
AU2005249231B2 (en) 2010-11-11
EA200602260A1 (ru) 2007-04-27
DK1753427T3 (da) 2008-07-21
BRPI0510414B1 (pt) 2022-04-05
ZA200609899B (en) 2009-01-28
ES2306146T3 (es) 2008-11-01
HRP20080307T3 (en) 2008-07-31
CA2566544C (en) 2012-04-17
KR20130024969A (ko) 2013-03-08
MY140611A (en) 2009-12-31
US20070249667A1 (en) 2007-10-25
US20100168133A1 (en) 2010-07-01
NO338624B1 (no) 2016-09-19
KR20070017393A (ko) 2007-02-09
CN1976704B (zh) 2012-12-05
EA010651B1 (ru) 2008-10-30
IL179630A0 (en) 2007-07-04
ATE390925T1 (de) 2008-04-15

Similar Documents

Publication Publication Date Title
AP2037A (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
HUS1500034I1 (hu) Indolidon-származékok fibrózisos betegségek kezelésére vagy megelõzésére
HK1113797A1 (en) Quinoline derivative for the treatment of retinal diseases
HK1186125A1 (en) Quinoline derivatives for the treatment of latent tuberculosis
GB0312832D0 (en) 2-amino-pyridine derivatives useful for the treatment of diseases
HK1096083A1 (en) Sulfonamide derivatives for the treatment of diseases
AP2006003669A0 (en) Sulfonamide derivatives for the treatment of diseases
IL184124A0 (en) Medicaments for the treatment or prevention of fibrotic diseases
ZA200705160B (en) Quinoline derivatives for the treatment of latent tuberculosis
GB0425054D0 (en) Formamide derivatives for the treatment of diseases
GB0408297D0 (en) Indole derivatives for the treatment of diseases
GB0312840D0 (en) 2-amino-pyridine derivatives useful for the treatment of diseases
GB0312842D0 (en) 2-amino-pyridine derivatives useful for the treatment of diseases
GB0406387D0 (en) Sulfonamide derivatives for the treatment of diseases
GB0406388D0 (en) Sulfonamide derivatives for the treatment of diseases
HK1096379A1 (en) Sulfonamide derivatives for the treatment of diseases